10 Stocks Flashing Strong Entry Buy Signals — August 2026

Decoding August 2026's Top 10 Strong Entry Stock Signals

As of August 28, 2026, the MarketsHost.com OpportunityRadar scan has identified a compelling set of stocks displaying strong buy signals. Leading the pack is Rapport Therapeutics, Inc. (RAPP) with an impressive OpportunityRadar Score of 67, driven by strong technicals (74) and solid fundamentals (56). RAPP also boasts significant recent performance, with a 1-month return of 20.52% and a 3-month return of 33.09%, all while flashing a 100% confidence BUY signal with a STRONG ENTRY rating.

This scan highlights a consistent theme among the top performers: all 10 profiled tickers exhibit a 100% confidence BUY signal with a STRONG ENTRY rating. Furthermore, every single one of these top 10 stocks shows a MACD in BULL territory, indicating positive momentum. Their RSI values generally sit in a healthy range, mostly between 55 and 65, suggesting upward potential without being immediately overbought. The average 1-month return for these top 10 tickers stands at approximately 15.5%, with an average 3-month return around 29.5%, underscoring a period of robust performance.

Top 10 Signals at a Glance

#1: RAPP — Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc. (RAPP) registers the highest OpportunityRadar Score in this scan at 67, indicating a robust overall outlook. Its technical score of 74 and fundamental score of 56 contribute to a 100% confidence BUY signal with a STRONG ENTRY rating. The stock's current price stands at $49.39. Technical indicators show an RSI of 58.9, alongside a MACD in BULL territory, suggesting positive price momentum. RAPP has demonstrated strong recent performance, with a 1-month return of 20.52% and a 3-month return of 33.09%.

Despite the strong signals, the Risk/Reward ratio for RAPP is noted at 0.7. While this indicates potential upside, it is relatively lower compared to some other opportunities in the scan, suggesting a more moderate risk-adjusted return profile based on this metric.

#2: VRTX — Vertex Pharmaceuticals Incorpo

Vertex Pharmaceuticals Incorporated (VRTX) earns an OpportunityRadar Score of 66, with technicals at 73 and fundamentals at 55. This combination results in a 100% confidence BUY signal and a STRONG ENTRY. Trading at $543.98, VRTX's technical picture includes an RSI of 62.8 and a MACD in BULL alignment, pointing to sustained buying interest. The stock has seen a 1-month return of 14.02% and a 3-month return of 24.08%, reflecting significant upward movement.

A notable factor for VRTX is its Risk/Reward ratio of 0.2. This low ratio suggests that the potential reward relative to the potential risk, as measured by the OpportunityRadar methodology, is quite limited. Investors should consider this metric carefully when evaluating the entry.

#3: SCSC — ScanSource, Inc.

ScanSource, Inc. (SCSC) shows an OpportunityRadar Score of 65, supported by a technical score of 73 and a fundamental score of 53. The scanner issues a 100% confidence BUY signal with a STRONG ENTRY, with the stock priced at $57.21. Technical analysis reveals an RSI of 58.3 and a MACD firmly in BULL territory, indicating positive momentum. Over the past three months, SCSC has delivered an 18.87% return, though its 1-month return is a more modest 1.04%.

While the overall signal is strong, the 1-month return of 1.04% for SCSC is among the lower figures within this top 10 list. This could suggest a recent consolidation period or slower short-term price appreciation compared to tickers with higher recent momentum, despite its robust 3-month performance.

#4: FTNT — Fortinet, Inc.

Fortinet, Inc. (FTNT) is rated with an OpportunityRadar Score of 65, featuring a technical score of 70 and a fundamental score of 58. The scan indicates a 100% confidence BUY signal and a STRONG ENTRY for the stock, currently trading at $164.31. Technical indicators for FTNT include an RSI of 55.5 and a MACD in BULL configuration, signaling positive price action. The stock has posted a 1-month return of 1.46% and a 3-month return of 11.67%.

Fortinet's Risk/Reward ratio stands at 0.6. While positive, this ratio is on the lower side among the profiled stocks, indicating a relatively less favorable risk-adjusted return profile compared to those with higher ratios, such as SCSC at 1.7.

#5: KOF — Coca Cola Femsa S.A.B. de C.V.

Coca Cola Femsa S.A.B. de C.V. (KOF) registers an OpportunityRadar Score of 65, with its technicals at 69 and fundamentals at 58. The scanner has identified a 100% confidence BUY signal and a STRONG ENTRY for KOF, which is priced at $112.79. The technical outlook shows an RSI of 56.9 and a MACD in BULL territory, indicating positive sentiment. Recent performance includes a 1-month return of 4.17% and a 3-month return of 5.75%.

The 3-month return of 5.75% for KOF is the lowest among the top 10 tickers, and its 1-month return of 4.17% is also comparatively modest. This suggests a slower pace of appreciation over recent periods despite the strong BUY signal and positive technical alignment.

#6: BIIB — Biogen Inc.

Biogen Inc. (BIIB) shows an OpportunityRadar Score of 65, with its technical score at 71 and fundamental score at 55. The stock, currently priced at $217.4, has a 100% confidence BUY signal and a STRONG ENTRY. Technical analysis reveals an RSI of 56.8 and a MACD in BULL status, indicating favorable momentum. BIIB has achieved a 1-month return of 7.12% and a 3-month return of 13.09%.

Biogen's Risk/Reward ratio is 0.3, which is among the lowest in this selection of stocks. This low ratio suggests that the potential upside, when weighed against the defined risk, is relatively constrained, requiring careful consideration for new entries.

#7: MRK — Merck & Company, Inc.

Merck & Company, Inc. (MRK) has an OpportunityRadar Score of 64, with technicals at 70 and fundamentals at 55. The scanner indicates a 100% confidence BUY signal and a STRONG ENTRY for MRK, trading at $147.65. Technical indicators show an RSI of 61.4 and a MACD in BULL alignment, suggesting continued positive price action. Merck has delivered strong returns, with a 1-month gain of 13.4% and a 3-month gain of 28.2%.

With an RSI of 61.4, MRK is positioned closer to the upper end of the neutral range, though not yet in overbought territory. This proximity suggests that while momentum is strong, close monitoring of its RSI trend would be prudent for potential entry points.

#8: NEO — NeoGenomics, Inc.

NeoGenomics, Inc. (NEO) receives an OpportunityRadar Score of 64, driven by strong technicals at 73 and fundamentals at 50. The stock, priced at $18.0, carries a 100% confidence BUY signal and a STRONG ENTRY rating. Its technical profile includes an RSI of 64.6 and a MACD in BULL territory, indicating robust upward momentum. NEO has shown exceptional performance, with a 1-month return of 17.72% and a remarkable 3-month return of 72.41%.

NeoGenomics’ RSI of 64.6 is the highest among the profiled stocks, placing it closer to the 70-mark often considered overbought. While not yet overbought, this higher RSI suggests that the stock has experienced significant upward movement recently, which could precede a period of consolidation or a pullback.

#9: ABUS — Arbutus Biopharma Corporation

Arbutus Biopharma Corporation (ABUS) has an OpportunityRadar Score of 64, with technicals at 71 and fundamentals at 53. The stock, trading at $5.09, is flagged with a 100% confidence BUY signal and a STRONG ENTRY. Technical analysis shows an RSI of 61.3 and a MACD in BULL alignment, indicating positive momentum. ABUS has recorded a 1-month return of 17.4% and a 3-month return of 13.73%.

The Risk/Reward ratio for ABUS is 0.7. While this is a positive ratio, it's important to compare it to other opportunities. It is lower than SCSC's 1.7 or NEO's 1.0, implying a more measured potential return for the associated risk.

#10: HNGE — Hinge Health, Inc.

Hinge Health, Inc. (HNGE) concludes our top 10 list with an OpportunityRadar Score of 64, featuring technicals at 69 and fundamentals at 56. Priced at $89.3, HNGE has a 100% confidence BUY signal and a STRONG ENTRY. Technical indicators include an RSI of 57.2 and a MACD in BULL territory, suggesting a favorable trend. The stock has shown strong recent gains, with a 1-month return of 19.53% and a 3-month return of 46.59%.

HNGE's Risk/Reward ratio is 0.7. While the stock demonstrates compelling recent returns, this ratio suggests a balanced risk-adjusted outlook. Investors seeking higher Risk/Reward profiles might find other opportunities in the scan more appealing based purely on this metric.

Key Observations Across the Scan

The current scan data for August 28, 2026, reveals a strong consensus among the top 10 tickers. All 10 stocks profiled show a 100% confidence BUY signal with a STRONG ENTRY rating, indicating a high degree of alignment across the OpportunityRadar's assessment criteria. Furthermore, every single one of these tickers exhibits a MACD in BULL territory, confirming robust positive momentum. The RSI values are generally healthy, ranging from 55.5 (FTNT) to 64.6 (NEO), suggesting upward potential without immediate signs of being overbought. Many of these stocks, such as NEO (72.41%), RIGL (53.92%, not in top 10 but notable), and HNGE (46.59%), have delivered substantial 3-month returns, highlighting a period of significant appreciation.

Key Risk Factors

• Low Risk/Reward Ratios: Several tickers exhibit notably low Risk/Reward ratios. For instance, Vertex Pharmaceuticals (VRTX) has a ratio of 0.2, Biogen Inc. (BIIB) shows 0.3, and Rapport Therapeutics (RAPP) has 0.7. These lower ratios suggest that the potential upside, as defined by the OpportunityRadar methodology, is relatively limited compared to the associated risk.
• Elevated RSI for Select Stocks: NeoGenomics, Inc. (NEO) stands out with an RSI of 64.6, which is the highest among the profiled stocks. While not yet in the typical overbought range (usually above 70), this higher RSI indicates substantial recent price appreciation and could signal that the stock is nearing a point where it might consolidate or experience a pullback.
• Absence of Detailed Data Points: Investors should note that explicit stop levels, price targets, support/resistance levels, and detailed fundamental metrics such as P/E, EPS, Debt/Equity, and earnings/revenue growth are marked N/A across all profiled tickers in this scan data. This means a comprehensive fundamental valuation or precise risk management parameters are not explicitly available within this specific scan's output.

About Our Methodology

OpportunityRadar scans 6,600+ US stocks daily using 15+ technical indicators including RSI, MACD, Bollinger Bands, ADX, Aroon, support/resistance levels, and volume analysis, combined with fundamental metrics. Stocks are scored 0-100 with signals ranging from Accumulate to Strong Buy. Entry confidence is rated 50-100% based on 6 confirmation factors.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. Past performance does not guarantee future results. Always conduct your own research and consult a qualified financial advisor before making investment decisions. Data as of August 28, 2026.